🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Dapagliflozin in Patients With Atrial Fibrillation (DAPA-AF)

RecruitingPhase 3Ages 18 Years - 85 YearsAllUniversity of Oklahoma
NCT05174052 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The study will investigate the effect of Dapagliflozin on atrial fibrillation (AF) burden. AF burden will be defined as the percent of time spent in AF over a 2-week period, assessed by noninvasive continuous heart rhythm monitoring at baseline and at 3 months, quality of life (QOL) and validated echocardiographic indices of atrial myopathy. This knowledge will enable us to study the therapeutic potential of SGLT2i as a novel adjunct treatment for patients with DM and AF. Patients with paroxysmal AF (AF that terminates spontaneously or with intervention within seven days of onset) and DM and randomize them to Dapagliflozin or placebo. Continuous heart rhythm monitoring patch for AF burden will be used, measure of QOL with the help of AF Effect on Quality-of-life survey and perform an echocardiogram with measurement of left atrial volume index, left atrial strain and atrial tissue doppler

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Diagnosed with DM * Paroxysmal AF Exclusion Criteria: * Type 1 DM, * Symptoms of hypotension or systolic blood pressure \<90mmHg, * Severe renal impairment with eGFR\<30mL/minute/1.73m2, * History of lower limb amputation, * Hypersensitivity to Dapagliflozin, * Currently taking any SGLT2i, * Pregnancy, * Currently taking anti-arrhythmic drugs * Undergoing catheter ablation will be excluded
💊

What it tests

  • Dapagliflozin 10Mg Tab
  • Placebo
📍

Where

1 site
University of Oklahoma Health Sciences Center
Oklahoma City, United States
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy